Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 28

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 28
---
 payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.

Each series of the notes will be issued under an indenture dated as of March 8, 2022 (the “indenture”), among the issuer, Boston Scientific, as guarantor, and U.S. Bank Trust Company, National Association, as trustee, and will be issued in minimum denominations of €100,000 and integral multiples of €1,000 in excess thereof. The notes will be deposited initially with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. U.S. Bank Europe DAC will act as paying agent and registrar for the notes. We may change any paying agent and registrar without notice to holders of the notes and may act as paying agent or registrar.

If any interest payment date, redemption date, or maturity date falls on a day that is not a business day at any place of payment, then the required payment of principal (or premium, if any) or interest, if any, will be made on the next succeeding business day at such place of payment as if made on the date that the payment was due and no interest will accrue on that payment for the period from and after the interest payment date, redemption date, or maturity date, as the case may be, to the date of payment on the next succeeding business day.

We may, at any time, without the consent of the holders of the applicable series of notes, issue additional notes of any series offered hereby having the same ranking and the same interest rate, maturity and other terms as such series (except for the payment of interest accruing prior to the issue date of such additional notes or, in some cases, the first interest payment date following the issue date of such additional notes), and, subject to certain tax considerations, any such additional notes of such series, together with the corresponding notes of such series offered by this prospectus supplement, will form a single series of such notes under the indenture. The notes will contain covenants that will restrict, with certain exceptions, the ability of Boston Scientific and its Subsidiaries to create, grant or incur liens and the ability of Boston Scientific and the issuer to merge or consolidate with another entity or transfer all or substantially all of the property and assets of Boston Scientific or the issuer, as applicable. See “